Dynatronics Corporation (DYNT): Price and Financial Metrics

DYNT Stock Price Chart Interactive Chart >

DYNT Price/Volume Stats

Dynatronics Corporation (DYNT) Company Bio

Dynatronics Corporation, a medical device company, designs, manufactures, and sells physical therapy, rehabilitation, orthopedics, pain management, and athletic training products in the United States. It offers orthopedic soft bracing products, which include cervical collars, shoulder immobilizers, arm slings, wrist and elbow supports, abdominal and lumbosacral supports, maternity supports, knee immobilizers and supports, ankle walkers and supports, plantar fasciitis splints, and cold therapy products. The company also provides power and manually operated treatment tables, mat platforms, work tables, parallel bars, training stairs, weight racks, treadmills, recumbent bikes, and other related equipment. In addition, it offers therapeutic modality devices, such as electrotherapy, ultrasound, phototherapy, therapeutic lasers, shortwave diathermy, radial pulse therapy, hot and cold therapy, compression therapy, and electrodes. Further, the company provides clinical supplies, including exercise bands and tubing, topical analgesics, lotions and gels, orthopedic bracing, paper products, athletic tapes, and other related supplies. It markets its products under the Bird & Cronin, Solaris, Hausmann, Physician's Choice, and PROTEAM brands. The company sells its products to orthopedists, physical therapists, chiropractors, and athletic trainers, sports medicine practitioners, hospitals, clinics, and consumers, as well as online. It also exports its products to approximately 30 countries. The company was founded in 1979 and is headquartered in Eagan, Minnesota.

DYNT Price Forecast Based on DCF Valuation

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Dynatronics Corp. To summarize, we found that Dynatronics Corp ranked in the 37th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 49.5%. In terms of the factors that were most noteworthy in this DCF analysis for DYNT, they are:

• The stock's equity weight, or the proportion of capital from equity relative to debt, is 69. Its equity weight surpasses that of merely 18.41% of free cash flow generating stocks in the Healthcare sector.
• Its compound free cash flow growth rate, as measured over the past 5.75 years, is -0.02% -- higher than only 21.4% of stocks in our DCF forecasting set.

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as DYNT, try OFIX, A, JNJ, PAHC, and ICUI.